CD274 and neoplasm: For SETD2_Y1666, the upregulation of HLA-I-dependent antigen presentation appeared to counterbalance the adverse effect of PD-L1-mediated immune evasion, reshaping the tumor immune microenvironment to favor anti-PD-1/PD-L1 immunotherapy.